A phase III, randomized, double-blind, placebo-controlled trial evaluating the ability of risedronate [risedronic acid] to prevent skeletal related events in patients with metastatic prostate cancer commencing hormonal therapy: Hoosier Oncology Group GU02-41.

Trial Profile

A phase III, randomized, double-blind, placebo-controlled trial evaluating the ability of risedronate [risedronic acid] to prevent skeletal related events in patients with metastatic prostate cancer commencing hormonal therapy: Hoosier Oncology Group GU02-41.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2016

At a glance

  • Drugs Risedronic acid (Primary)
  • Indications Cancer metastases; Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 25 May 2016 Status changed from active, no longer recruiting to discontinued.
    • 05 Jun 2010 Results presented at ASCO 2010.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top